64 related articles for article (PubMed ID: 22239500)
1. Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection.
Jafferbhoy H; Miller MH; Dunbar JK; Tait J; McLeod S; Dillon JF
J Viral Hepat; 2012 Feb; 19(2):112-9. PubMed ID: 22239500
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants.
Jeffrey GP; MacQuillan G; Chua F; Galhenage S; Bull J; Young E; Hulse G; O'Neil G
Hepatology; 2007 Jan; 45(1):111-7. PubMed ID: 17187435
[TBL] [Abstract][Full Text] [Related]
3. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients.
Bruggmann P; Falcato L; Dober S; Helbling B; Keiser O; Negro F; Meili D;
J Viral Hepat; 2008 Oct; 15(10):747-52. PubMed ID: 18637072
[TBL] [Abstract][Full Text] [Related]
4. Survival in HIV-infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database.
Voirin N; Trépo C; Miailhes P; Touraine JL; Chidiac C; Peyramond D; Livrozet JM; Ritter J; Chevallier P; Fabry J; Allard R; Vanhems P
J Viral Hepat; 2004 Nov; 11(6):559-62. PubMed ID: 15500557
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C.
Bate JP; Colman AJ; Frost PJ; Shaw DR; Harley HA
J Gastroenterol Hepatol; 2010 Jul; 25(7):1276-80. PubMed ID: 20594255
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance.
Schulte B; Schütt S; Brack J; Isernhagen K; Deibler P; Dilg C; Verthein U; Haasen C; Reimer J
Drug Alcohol Depend; 2010 Jun; 109(1-3):248-51. PubMed ID: 20167441
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders.
Chainuvati S; Khalid SK; Kancir S; Shea M; Edwards J; Sernyak M; Wongcharatrawee S; Garcia-Tsao G
J Viral Hepat; 2006 Apr; 13(4):235-41. PubMed ID: 16611189
[TBL] [Abstract][Full Text] [Related]
8. Sexual activity as a risk factor for hepatitis C in Puerto Rico.
De Jesús-Caraballo J; Toro DH; Rodríguez-Pérez F; Ruiz H; Dueño MI; Alvarez M; Suárez-Pérez E;
Bol Asoc Med P R; 2008; 100(3):15-20. PubMed ID: 19227710
[TBL] [Abstract][Full Text] [Related]
9. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
Mehta SH; Lucas GM; Mirel LB; Torbenson M; Higgins Y; Moore RD; Thomas DL; Sulkowski MS
AIDS; 2006 Nov; 20(18):2361-9. PubMed ID: 17117023
[TBL] [Abstract][Full Text] [Related]
10. A French prospective observational study of the treatment of chronic hepatitis C in drug abusers.
Chossegros P; Mélin P; Hézode C; Bourlière M; Pol S; Fhima A; Filoche B; Trépo C; Couzigou P; Ouzan D; Gagnon A
Gastroenterol Clin Biol; 2008 Oct; 32(10):850-7. PubMed ID: 18805662
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
12. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE;
Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240
[TBL] [Abstract][Full Text] [Related]
13. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.
Reiberger T; Obermeier M; Payer BA; Baumgarten A; Weitner L; Moll A; Christensen S; Köppe S; Kundi M; Rieger A; Peck-Radosavljevic M
Antivir Ther; 2011; 16(6):815-24. PubMed ID: 21900713
[TBL] [Abstract][Full Text] [Related]
14. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin.
Stark K; Müller R; Bienzle U; Guggenmoos-Holzmann I
AIDS; 1996 Mar; 10(3):311-7. PubMed ID: 8882671
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C treatment for injection drug users: a review of the available evidence.
Hellard M; Sacks-Davis R; Gold J
Clin Infect Dis; 2009 Aug; 49(4):561-73. PubMed ID: 19589081
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus.
Pham TN; Coffin CS; Churchill ND; Urbanski SJ; Lee SS; Michalak TI
J Viral Hepat; 2012 Feb; 19(2):103-11. PubMed ID: 21699630
[TBL] [Abstract][Full Text] [Related]
17. Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre.
Islam MM; Topp L; Conigrave KM; White A; Reid SE; Grummett S; Haber PS; Day CA
J Subst Abuse Treat; 2012 Dec; 43(4):440-5. PubMed ID: 22938915
[TBL] [Abstract][Full Text] [Related]
18. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A;
Int J Drug Policy; 2015 Oct; 26(10):999-1006. PubMed ID: 26275578
[TBL] [Abstract][Full Text] [Related]
19. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network.
Morris L; Smirnov A; Kvassay A; Leslie E; Kavanagh R; Alexander N; Davey G; Williams O; Gilks C; Najman J
Int J Drug Policy; 2017 Sep; 47():216-220. PubMed ID: 28666635
[TBL] [Abstract][Full Text] [Related]
20. Management of hepatitis C virus infection in heavy drinkers.
Costentin CE; Trabut JB; Mallet V; Darbeda S; Thépot V; Nalpas B; Badin de Montjoye B; Lavielle B; Vallet-Pichard A; Sogni P; Pol S
Alcohol Alcohol; 2013; 48(3):337-42. PubMed ID: 23518789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
